MedCity News March 3, 2024
A federal judge disagreed with AstraZeneca’s claims that the Inflation Reduction Act causes harm by disincentivizing innovation and violates its constitutional rights to due process. Blockbuster AstraZeneca drug Farxiga is one of 10 medications selected for the Medicare drug price negotiation program created by the law.
AstraZeneca has lost its lawsuit challenging Medicare’s drug price negotiation program after a federal judge concluded the pharmaceutical giant has no standing to contest the law that created it, nor does the company have a constitutionally protected property interest in the matter.
The decision issued Friday is the first of several lawsuits filed by pharmaceutical companies in opposition to certain provisions of the law, the Inflation Reduction Act (IRA). Many of them make constitutional...
Today's Sponsors
Today's Sponsor